1[1]Liu PP, Opavsky MA. Viral myocarditis: receptors that bridge the cardiovascular with the immune system? Circ Res, 2000, 86253～254.
2[2]Leipner C, Grun K, Borchers M, et al. The outcome of coxsackievirus B3-(CVB3-) induced myocarditis is influenced by the cellular immune status. Herz, 2000, 25245～248.
3[3]Schwimmbeck PL, Rohn G, Wrusch A. Enteroviral and immune mediated myocarditis in SCID mice.Herz, 2000, 25240～244.
4[4]Schwimmbeck PL, Badorff C, Rohn G,et al.The role of sensitized T-cells in myocarditis and dilated cardiomyopathy. Int J Cardiol, 1996, 54117～125.
5[5]McLaughlin L, Zhu G, Mistry M, et al. The immune response following myocardial infarction: a role for T-cell-mediated myocyte damage. J Mol Cell Cardiol, 2000, 322107～2110.
6[6]Slifka MK, Pagarigan R, Mena I, et al. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J Virol, 2001, 752377～2387.
7[7]Schmidtke M, Gluck B, Merkle I,et al. Cytokine profiles in heart, spleen, and thymus during the acute stage of experimental coxsackievirus B3-induced chronic myocarditis. J Med Virol, 2000, 61518～526.
8[8]Maisch B, Portig I, Ristic A. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report. Herz, 2000,25200～209.
9[9]Binah O. Immune effector mechanisms in myocardial pathologies. Int J Mol Med, 2000, 63～16.
10[10]Gluck B, Merkle I, Dornberger G,et al. Expression of inducible nitric oxide synthase in experimental viral myocarditis. Herz, 2000, 25255～260.
